A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency (HEART-FID) (Protocol # 1VIT15043)

Study Details

This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) for patients in heart failure with iron deficiency.

Learn More

ClinicalTrials.gov NCT number

Principal Investigators

  • David Hsi, MD
Luitpold Pharmaceuticals
Juan Garcia, RN at 203-358-8879
or officeofresearch@stamhealth.org